About Centriolar and ciliogenesis-associated protein HYLS1
Centriolar and ciliogenesis-associated protein HYLS1 (HYLS1) is a protein
from Homo sapiens identified by UniProt accession
Q96M11, 299 residues long.
MolForge cross-references it against 0 known binders and
89 disease associations.
Target properties
| Protein name | Centriolar and ciliogenesis-associated protein HYLS1 |
|---|
| UniProt accession | Q96M11 |
|---|
| Gene | HYLS1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 299 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (89)
Diseases linked to this target (Open Targets).
- Hydrolethalus · score 0.71
- hydrolethalus syndrome · score 0.67
- Joubert syndrome · score 0.63
- severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome · score 0.53
- neurodegenerative disease · score 0.45
- genetic disorder · score 0.34
- Polyhydramnios · score 0.33
- Abnormal heart morphology · score 0.33
- anencephaly · score 0.33
- congenital heart disease · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96M11-F1 | alphafold | PREDICTED | 65.53 | — |
Amino-acid sequence (299 residues)
MEELLPDGQI WANMDPEERM LAAATAFTHI CAGQGEGDVR REAQSIQYDP YSKASVAPGK RPALPVQLQY PHVESNVPSE TVSEASQRLR KPVMKRKVLR RKPDGEVLVT DESIISESES GTENDQDLWD LRQRLMNVQF QEDKESSFDV SQKFNLPHEY QGISQDQLIC SLQREGMGSP AYEQDLIVAS RPKSFILPKL DQLSRNRGKT DRVARYFEYK RDWDSIRLPG EDHRKELRWG VREQMLCRAE PQSKPQHIYV PNNYLVPTEK KRSALRWGVR CDLANGVIPR KLPFPLSPS
Explore Centriolar and ciliogenesis-associated protein HYLS1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets